Dutch biotech company Agendia BV, announced today the closing of a third financing round with the Van Herk Group and Gilde Healthcare. Agendia is the first company world wide to commercialize microarray-based diagnostics. MammaPrint®, its prognostic breast cancer test, assesses the risk of breast cancer recurrence based on the activity of key genes. The information of this 70 gene profile, which has been published in papers such as Nature and the New England Journal of Medicine and has been (independently) validated in several studies, is superior to classical criteria such as the St. Gallen Consensus or NIH criteria in predicting outcome of disease. Its second microarray product, CupPrint®, is a diagnostic test which was commercialized in 2005 to identify the origin of a metastasis in a cancer type called "Cancer of Unknown Primary".
